Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (351-360 of 584) with videos related to

Pageof 59
Sort By:
Plos One|July 16, 2011
Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemiaJaroslav Jelinek, Vazganush Gharibyan, Marcos R H Estecio, et al.
Blood|June 17, 2004
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alphaHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
Blood|February 29, 2012
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureH Jean Khoury, Jorge E Cortes, Hagop M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemiaFrancis J Giles, Guillermo Garcia-Manero, Jorge E Cortes, et al.
Leukemia & Lymphoma|November 9, 2001
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndromeB S Dabaja, S M O'Brien, H M Kantarjian, et al.
Haematologica|August 26, 2003
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylateSimona Gatto, Barbara Scappini, Lan Pham, et al.
Blood|September 26, 2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMartin C Müller, Jorge E Cortes, Dong-Wook Kim, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2003
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemiaApostolia M Tsimberidou, Elihu Estey, Jorge E Cortes, et al.
Blood Advances|May 13, 2020
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromeJe-Hwan Lee, Stefan Faderl, John M Pagel, et al.
Pageof 59

Showing results (351-360 of 584) with videos related to

Sort By:
Pageof 59
Plos One|July 16, 2011
Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemiaJaroslav Jelinek, Vazganush Gharibyan, Marcos R H Estecio, et al.
Blood|June 17, 2004
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alphaHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
Blood|February 29, 2012
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureH Jean Khoury, Jorge E Cortes, Hagop M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemiaFrancis J Giles, Guillermo Garcia-Manero, Jorge E Cortes, et al.
Leukemia & Lymphoma|November 9, 2001
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndromeB S Dabaja, S M O'Brien, H M Kantarjian, et al.
Haematologica|August 26, 2003
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylateSimona Gatto, Barbara Scappini, Lan Pham, et al.
Blood|September 26, 2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMartin C Müller, Jorge E Cortes, Dong-Wook Kim, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2003
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemiaApostolia M Tsimberidou, Elihu Estey, Jorge E Cortes, et al.
Blood Advances|May 13, 2020
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromeJe-Hwan Lee, Stefan Faderl, John M Pagel, et al.
Pageof 59